Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 78 of 1120 for:    Oral Cancer | ( Map: Canada )

Histamine Receptor 2 Antagonists as Enhancers of Anti-Tumour Immunity

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03145012
Recruitment Status : Active, not recruiting
First Posted : May 9, 2017
Last Update Posted : March 11, 2019
Sponsor:
Collaborators:
Nova Scotia Health Authority
Dalhousie University
Information provided by (Responsible Party):
Lisa Barrett, Nova Scotia Health Authority

Brief Summary:

The immune response against tumors can be highly effective in preventing tumor development, growth and metastasis under certain circumstances. However, tumor associated immune suppression can profoundly limit the impact of natural tumor immunity and also reduce the effectiveness of tumor immunotherapy strategies.

A major component of tumor associated immune suppression is mediated by myeloid cells, especially the monocytic subset of myeloid derived suppressor cells (MDSC). In recent studies that were conducted through a CCSRI Innovation grant, the investigators discovered that oral treatment of mice with the commonly used histamine receptor 2 (H2) antagonists ranitidine or famotidine inhibits both primary breast tumor development and metastasis, in three distinct mouse tumor models and reduces the numbers of monocytic MDSC. These findings have enormous potential to aid in effective cancer immunotherapy and may have immediate implications for cancer patients.

The objective of this investigation is to determine whether treatment with the H2 receptor antagonist ranitidine alters immune suppression, through modulation of immune cell populations.

The investigators will examine peripheral blood monocyte, neutrophil and NK cell numbers, subsets and activation status from healthy volunteers treated for 6 weeks with daily oral ranitidine.

Ranitidine is widely available and used over the counter in Canada. These drugs are widely recognized as safe, well tolerated and have very few side effects. It has been suggested that among the general population, over 10% of those over the age of 65 take such medications on a regular basis for relief against gastrointestinal discomfort. The outcome of pre-clinical studies in mice warrant further investigation into transferability to humans.

If the outcome of the current proposal proves to be viable, then these drugs could provide a safe method to reduce tumor associated immunosuppression with broad implications, both for current cancer patients and for those at high risk of developing cancer. Further to this, the outcome of our proposal may provide a new strategy for improving the effectiveness of T-cell mediated immunotherapy.


Condition or disease Intervention/treatment Phase
Cancer Drug: Ranitidine Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Intervention Model: Single Group Assignment
Intervention Model Description: Healthy individuals will be asked to take ranitidine for 6 weeks to determine the effect on peripheral blood immune cells.
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Histamine Receptor 2 Antagonists as Enhancers of Anti-Tumour Immunity
Actual Study Start Date : May 1, 2018
Estimated Primary Completion Date : November 1, 2019
Estimated Study Completion Date : November 1, 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Treatment Group

This is a one arm study in which all individuals receive the treatment; therefore there is no allocation or randomization.

Thirty subjects will receive ranitidine to a maximum of 900 mg/day in 2 daily doses for 6 weeks. The dosage target is 8 mg/kg/day, but the range of ranitidine intake will be between 7.5- 9 mg/kg/day. This is due to the formulation of the tablets, sold as 75, 150, and 300mg tablets. The ranitidine will be taken orally.

Drug: Ranitidine
Thirty subjects will receive Ranitidine to a maximum of 900 mg/day in 2 daily oral doses for 6 weeks. The dosage target is 8 mg/kg/day, but the range of ranitidine intake will be between 7.5- 9 mg/kg/day. This is due to the formulation of the tablets, sold as 75, 150, and 300mg tablets.
Other Name: Zantac




Primary Outcome Measures :
  1. Intra-individual frequency and function of immune cell subsets [ Time Frame: Frequency and function were calculated as the values at 6 wks after treatment compared to the values at baseline. ]
    To determine the effect of histamine 2 receptor antagonists on immune cell function in healthy humans. Frequency and function of B cell, T cell, monocyte, NK cell and MDSC cells will be assessed by flow cytometry and ELISPOT.


Secondary Outcome Measures :
  1. Inter-individual frequency and function of immune cell subsets [ Time Frame: Frequency and function were calculated as the values at 6 wks after treatment compared to the values at baseline. ]
    To determine the effect of histamine 2 receptor antagonists on immune cell function cross-sectionally. B cell, T cell, monocyte, NK cell and MDSC cells will be assessed by flow cytometry and ELISPOT.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Age 20-50 years old, all sexes or genders
  • Veins acceptable for blood draw
  • Able to provide informed consent
  • eGFR > 90 mL/min/1.73m2
  • Have no clinically significant diseases captured in the medical history or evidence of clinically significant findings on physical examination and/or clinical laboratory evaluations (hematology, biochemistry, ECG, urinalysis). Clinical laboratory values within stated normal range; if not within this range, they must be without clinical significance
  • Female volunteers who are of childbearing potential that agree to use of the accepted contraceptive regimens from at least 21 days prior to the first administration of study drug, during the study, and for at least 30 days after the last dose of study drug
  • Female volunteers who are postmenopausal (no menses for at least 1 year, or surgically sterile

Exclusion Criteria:

  • Use of ranitidine for greater than 1 week within 6 months of starting the study
  • Medical requirement for ranitidine use
  • Current or past diagnosis of: porphyria, cancer, immune deficiency disorder
  • Active infection at the time of screening
  • Known liver, hematologic, renal disease
  • Past history of allergic reaction to ranitidine or past history of hypersensitivity to any ingredient in the formulation or past history of hypersensitivity to other drugs
  • Pregnant, planning to be pregnant, or breastfeeding during the study period
  • Weight (kg) exceeds 109kg

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03145012


Locations
Layout table for location information
Canada, Nova Scotia
Nova Scotia Health Authority
Halifax, Nova Scotia, Canada, B3H 1V7
Sponsors and Collaborators
Lisa Barrett
Nova Scotia Health Authority
Dalhousie University
Investigators
Layout table for investigator information
Principal Investigator: Lisa Barrett, MD/PhD Nova Scotia Health Authority

Layout table for additonal information
Responsible Party: Lisa Barrett, Associate Professor, Nova Scotia Health Authority
ClinicalTrials.gov Identifier: NCT03145012     History of Changes
Other Study ID Numbers: SAIL-002
First Posted: May 9, 2017    Key Record Dates
Last Update Posted: March 11, 2019
Last Verified: March 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: There is no plan to share the IPD with other researchers.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Keywords provided by Lisa Barrett, Nova Scotia Health Authority:
Cancer
Immunity
Peripheral Blood Mononuclear Cells
Ranitidine

Additional relevant MeSH terms:
Layout table for MeSH terms
Histamine
Histamine phosphate
Ranitidine
Ranitidine bismuth citrate
Histamine Agonists
Histamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Anti-Ulcer Agents
Gastrointestinal Agents
Histamine H2 Antagonists
Histamine Antagonists